Integrated analysis of genomic and epigenomic alterations in circulating tumor DNA in patients with biliary tract cancer - COSMOS-BTC-01

ational Cancer Center Hospital East0 个研究点目标入组 110 人开始时间: 2023年11月14日最近更新: 2024年9月2日

适应症

试验速览

暂无简介。

•1.History of malignancy with a disease-free period of 5 years or less. *1 2.Clinically suspected coexistence of cancer of other organs. 3.Women who are pregnant or intend to become pregnant. 4.Judged by physician to be unsuitable for enrolment in the study. *1Pre-existing cancer with a disease-free interval of less than 5 years, but with a 5-year relative survival equivalent to 95% or more, such as stage I prostate cancer, stage 0 or stage I laryngeal cancer with a complete response to radiotherapy, or cancer of the following pathological stages that has been completely resected, will not be excluded and will be eligible for enrolment. Gastric cancer (adenocarcinoma [general type]): Stage 0 - Stage I Colorectal cancer (adenocarcinoma): Stage 0 - Stage I Esophageal cancer (flat epithelial carcinoma, adeno flat epithelial carcinoma, basaloid carcinoma): Stage 0 Breast cancer (non-invasive ductal carcinoma, non-invasive lobular carcinoma): stage 0 Breast cancer (invasive ductal carcinoma, invasive lobular carcinoma, Paget's disease): stage 0-IIA Uterine body cancer (endometrioid adenocarcinoma, mucinous adenocarcinoma): stage IA Anterior adenocarcinoma (adenocarcinoma): Stage I - IIA Cervical Cancer (Flat Epithelial Carcinoma): Stage IA Thyroid Cancer (Breast Cancer, Follicular Cancer): Stage I, II, III Kidney Cancer (Haplocellular Carcinoma, Haplocellular Carcinoma): Stage I Other Intramucosal Cancer Comparable Transformation

发起方

ational Cancer Center Hospital East